Depression and anxiety in female patients with cancer are serious comorbidities that affect the quality of life for patients and their survival rates as they have poorer health outcomes. This validation study is a part of the study on the prevalence of depression and anxiety among breast cancer patients. This study aims to investigate the validity of the Kazakh and Russian versions of the Beck Depression Inventory (BDI-II) and Beck Anxiety Inventory (BAI) among female cancer patients in Almaty, Kazakhstan.
Age range
18 Years – 65 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
BDI-II Score at Baseline:
Timeframe: Baseline
BDI-II Score on day 14
Timeframe: Day 14
BAI Score at Baseline
Timeframe: Baseline
BAI Score Day 14
Timeframe: Day 14
ICD-10 diagnosis at baseline
Timeframe: Baseline
ICD-10 diagnosis on Day 14
Timeframe: Day 14
Internal consistency of the BAI
Timeframe: Day 14
Internal consistency of the BDI-II
Timeframe: Day 14
Test - retest reliability of the BDI-II questtionaire
Timeframe: Day 14
Test - retest reliability of the BAI questtionaire
Timeframe: Day 14
Sensitivity and Specificity of the BDI-II at baseline
Timeframe: Baseline
Sensitivity and Specificity of the BAI at baseline
Timeframe: Baseline